

4th Vaccine and ISV Annual Global Congress Oral Programme

Sunday 3 October 2010

08:30	Conference Registration <i>Park Congress Lobby</i>
10:30 – 12:00	Opening Session & Plenary Session 1 <i>Park Congress</i> Session Chair: Ray Spier
10:30 – 10:40	Opening remarks: Shan Lu
10:40 – 11:20	[O1.1] Infectious disease vaccines in the light of unmet medical need, new technologies and challenges Alexander Von Gabain, <i>Intercell, Austria</i>
11:20 – 12:00	[O1.2] Expanding immunization against human <i>Salmonella</i> infections: vaccines to prevent invasive non-typhoidal <i>Salmonella</i> infections emerging in sub-Saharan Africa and <i>Salmonella</i> Paratyphi A in Asia Myron Levine, <i>University of Maryland, USA</i>
12:00 – 13:30	Satellite Symposium (GSK) <i>Park Congress</i> 
12:00 – 14:00	Lunch <i>Klimt Ballroom on level M1</i>
14:00 – 15:30	Plenary Session 2 <i>Park Congress</i> Control major infectious diseases in the world Session Chair: John Shiver
14:00 – 14:25	[O2.1] Phase III HIV Vaccine Trial (RV144): Preliminary Immunogenicity findings Mark DeSouza, <i>US Military Medical Research, USA</i>
14:25 – 14:50	[O2.2] The RTS,S malaria vaccine candidate: from concept to pivotal phase 3 testing Joe Cohen, <i>GlaxoSmithKline Biologicals, Belgium</i>
14:50 – 15:10	[O2.3] Clinical trials of antigen-antibody complex-based therapeutic vaccine for viral hepatitis B: the present and the future Yumei Wen, <i>Fudan University, China</i>
15:10 – 15:20	[O2.4] A novel therapeutic and prophylactic vaccine against tuberculosis using the cynomolgus monkey model and mouse model M. Okada ^{1,2} , Y. Kita ¹ , N. Kanamaru ¹ , Y. Kaneda ² , E. V. Tan ³ , D. McMurray ⁴ , ¹ <i>National Hospital Organization Kinki-chuo Chest Medical Center, Japan</i> , ² <i>Osaka University, Japan</i> , ³ <i>Leonard Wood Memorial Institute, Philippines</i> , ⁴ <i>Texas A&M University, USA</i>
15:20 – 15:30	[O2.5] Evaluation of a multi-component vaccine for malaria K. Radosevic, A. Rodriguez*, A.A.C. Lemckert, M. van der Meer, G. Gillissen, C. Warnar, et al; <i>Crucell Holland BV, Netherlands</i>
15:30 – 16:00	Refreshment Break <i>Level M1</i>
16:00 – 18:05	Plenary Session 3 <i>Park Congress</i> Gene-based and subunit vaccines Session Chair: Peter Nara
16:00 – 16:25	[O3.1] Potent as well as protective immune responses induced by highly engineered DNA vaccines delivered by Collectra™ EP in Nonhuman Primates and Humans David Weiner, <i>University of Pennsylvania, USA</i>
16:25 – 16:50	[O3.2] Development of universal influenza virus vaccines Adolfo Garcia-Sastre, <i>Mount Sinai School of Medicine, USA</i>
16:50 – 17:15	[O3.3] Recombinant envelope protein domain III as a dengue vaccine candidate? Alan Barrett, <i>University of Texas, USA</i>
17:15 – 17:25	[O3.4] Improved vectored vaccine regimes using co-administration of viral vectors A. Reyes-Sandoval*, C. Rollier, A.V.S. Hill, <i>The Jenner Institute, UK</i>
17:25 – 17:35	[O3.5] Characterization of a single-cycle rabies virus based vaccine vector M.J. Schnell*, <i>Thomas Jefferson University, USA</i>
17:35-17:45	[O3.6] Live measles virus as a vector for vaccine development A. Habel ¹ , E. Tauber ¹ , P. Despres ² , F. Tangy ² , ¹ <i>Themis Bioscience, Austria</i> , ² <i>Institut Pasteur, France</i>
17:45 – 17:55	[O3.7] Development of a filovirus-like vaccine for prevention of ebola- and marburgvirus hemorrhagic fever K.L. Warfield ¹ , J.M. Dye ² , D.L. Swenson ¹ , J.B. Wells ² , S. Bavari ² , M.J. Aman ¹ , ¹ <i>Integrated Biotherapeutics, Inc., USA</i> , ² <i>USA Army Research Institute of Infectious Diseases, USA</i>
17:55 – 18:05	[O3.8] Field trial of H5 subtype avian influenza DNA vaccine Y.P. Jiang, G.J. Wang, J.P. Li, J.X. Liu, G.B. Tian, H.L. Chen*, <i>Chinese Academy of Agricultural Sciences, China</i>
18:05 – 19:30	Poster/Exhibition Session 1 and Welcome Reception <i>Level M1</i>

Monday 4 October 2010

08:30 – 10:30	Plenary Session 4 Park Congress Vaccine Pipelines Session Chair: Shan Lu		
08:30 – 08:55	[O4.1] The development of prevar 13: a second-generation vaccine for the prevention of pneumococcal disease Emilio Emini, <i>Pfizer, USA</i>		
08:55 – 09:20	[O4.2] Creating innovative vaccines for the 21st Century Christian Mandl, <i>Novartis, USA</i>		
09:20 – 09:45	[O4.3] Utilization of traditional and new technologies for novel vaccine development John Shiver, <i>Merck, USA</i>		
09:45 – 09:55	[O4.4] Recombinant live attenuated Japanese encephalitis vaccine F. Guirakhoo*, C. Meric, E. Feroldi, <i>Sanofi Pasteur, France</i>		
09:55 – 10:05	[O4.5] ACE527, an oral live attenuated vaccine against enterotoxigenic E. coli (ETEC), is well tolerated and immunogenic in healthy adult volunteers M.J. Darsley* ¹ , C. Buchwaldt ¹ , C. Harro ² , B. DeNearing ² , D.A. Sack ² , A.L. Bourgeois ³ , R. Walker ³ , ¹ <i>TD Vaccines A/S, Denmark</i> , ² <i>Johns Hopkins University, USA</i> , ³ <i>PATH, USA</i>		
10:05 – 10:15	[O4.6] DENVax: a tetravalent recombinant dengue vaccine in phase I clinical testing D.T. Stinchcomb* ¹ , C. H.-Y. Huang ² , R. M. Kinney ¹ , S. George ³ , I. D. Velez ⁵ , J. E. Osorio ⁵ , ¹ <i>Inviragen, Inc., USA</i> , ² <i>CDC, USA</i> , ³ <i>St. Louis University, USA</i> , ⁴ <i>Universidad de Antioquia, Colombia</i> , ⁵ <i>University of Wisconsin, USA</i>		
10:15 – 10:25	[O4.7] Affinity purification of a live attenuated influenza virus from MDCK cell culture S. Hsu*, Y. Liu, H. Zhang, M. Thompson, <i>MedImmune, USA</i>		
10:30 – 11:00	Refreshment Break Level M1		
	Breakout Session 2 Park Congress 1&2 Vaccine Safety Session Chairs: Ray Spier and Jan Bonhoeffer	11:00 – 12:30	Breakout Session 1 Park Congress 3 JSV Sponsored Session Session Chair: Hiroshi Kiyono
11:00 – 11:15	[B2.1] The need to reconsider Phase III trial size Ray Spier, <i>University of Surrey, UK</i>	11:00 – 11:25	[B1.1] MucoNanogel antigen delivery system for adjuvant-free nasal vaccines Hiroshi Kiyono, <i>University of Tokyo, Japan</i>
11:15 – 11:30	[B2.2] Impact of a post-licensure management plan on Phase III trial size- industry perspective Thomas Vertraeten, <i>GlaxoSmithKline Biologicals, Belgium</i>	11:25 – 11:50	[B1.2] Post- and pre-exposure vaccination with a highly-attenuated smallpox vaccine, LC16m8, and efficacy in protection of nonhuman primates from lethal monkeypox Masayuki Saijo, <i>National Institute of Infectious Disease, Japan</i>
11:30 – 11:45	[B2.3] Cancelled	11:50 – 12:00	[B1.3] Oral immunization with <i>znuA</i>-deficient <i>Brucella melitensis</i> mutant protects against nasal <i>B. melitensis</i> challenge D.W. Pascual*, J.A. Skyberg, X. Yang, T. Thornburg, B. Clapp, <i>Montana State University, USA</i>
11:45 – 12:00	[B2.4] New approaches to safety assessment post licensure (SCCS + Rapid cycle analyses) – statistical perspective Nick Andrews, <i>Health Protection Agency, UK</i>	12:00 – 12:10	[B1.4] Lymph node resident dendritic cells capture influenza virus in a SIGN-R1 dependent mechanism and are essential for humoral immunity S.F. Gonzalez* ¹ , M.P. Kuligowski ¹ , L.A. Pitcher ¹ , V. Lukacs-Kornek ² , S.J. Turley ² , M.C. Carroll ¹ , ¹ <i>Harvard Medical School, USA</i> , ² <i>Dana Farber Cancer Institute, USA</i>
12:00 – 12:15	[B2.5] A global infrastructure for large data linkage is possible. Jan Bonhoeffer, <i>The Brighton Collaboration, Switzerland</i>	12:10 – 12:20	[B1.5] Peptide microarray for mapping HIVgp160 epitopes after vaccination of rhesus monkeys against HIV/SIV with modified vaccinia ankera or adenovirus vectors A. Abd El Wahed* ¹ , U. Beutling ² , C. Stahl-Hennig ³ , R. Frank ² , G. Hunsmann ¹ , H.-J. Fritz ¹ , ¹ <i>Georg August University Goettingen, Germany</i> , ² <i>Helmholtz Centre for Infection Research, Germany</i> , ³ <i>German Primate Center, Germany</i>

12:15 – 12:30	Panel Discussion	12:20 – 12:30	[B1.6] Cancelled
12:30 – 13:30	Lunch <i>Klimt Ballroom on level M1</i>		
13:30 – 15:30	Poster and Exhibition Session 2 <i>level M1</i>		
14:00 – 14:30	ISV Business Meeting Chair: Ray Spier		
15:30 – 17:40	Plenary Session 5 <i>Park Congress</i> Global vaccine development and vaccine efficacy Session Chair: Annie DeGroot		
15:30 – 15:55	[O5.1] Novel influenza vaccine strategies to address a global need Rick Bright, <i>PATH, USA</i>		
15:55 – 16:20	[O5.2] A novel replication-defective virus based platform for 3rd generation flavivirus vaccines Konstantin Pugachev, <i>Sanofi Pasteur, USA</i>		
16:20 – 16:30	[O5.3] Cost-effectiveness analysis of universal newborn vaccination against Hepatitis B virus in Vietnam: application of cost-effectiveness affordability curves in health-decision making H.A. Tu, R. de Vries, H.J. Woerdenbag, M. van Hulst, M.J. Postma*, <i>University of Groningen, Netherlands</i>		
16:30 – 16:40	[O5.4] Quantifying the 'population access time' for new vaccine: a European comparative study R.R. Reinert, C. Saint Sardos, S. Gaisch, J. Patris*, <i>European Vaccine Manufacturer, Belgium</i>		
16:40 – 16:50	[O5.5] Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs K. Stiasny*, H. Holzmann, F.X. Heinz, <i>Medical University of Vienna, Austria</i>		
16:50 – 17:00	[O5.6] Is low/non-responsiveness an antigen specific phenomenon? – an investigation with tick borne encephalitis (TBE) and hepatitis B non-responders E. Garner-Spitzer*, A. Wagner, M. Paulke-Korinek, H. Kollaritsch, F.X. Heinz, U. Wiedermann, <i>Medical University of Vienna, Austria</i>		
17:00 – 17:10	[O5.7] Possible herd immunity in the elderly following vaccination of schoolchildren with live, attenuated influenza vaccine A.M. McBean* ¹ , H.F. Hull ² , H. O'Connor ¹ , ¹ <i>University of Minnesota, USA</i> , ² <i>HF Hull & Associates, USA</i>		
17:10 – 17:20	[O5.8] The impact of additional 5 th and 6 th pertussis vaccine doses on disease incidence in children and infants C. Stein-Zamir*, H. Shoob, N. Abramson, G. Zentner, <i>Jerusalem District Health Office, Israel</i>		
17:20 – 17:30	[O5.9] Estimating the effector T cell response to DNA-vaccination in rhesus macaques and humans D.J. Shedlock*, J. Yan, J. Yin, P. Pankhong, A. Dai, T.H. Shin, et al, <i>University of Pennsylvania, USA</i>		
17:30 – 17:40	[O5.10] Immunization with HSV-2 glycoprotein C and D: an immune evasion based novel vaccine design for HSV-2 disease S. Awasthi*, J.M. Lubinski, S.M. Barrett, C.E. Shaw, M. Cai, H.M. Friedman, <i>University of Pennsylvania, USA</i>		
17:40-17:50	[O5.11] Development, Optimisation and Validation of ELISA for the quantification of HCP To be determined, <i>Covance</i>		
17:50-18:00	[O5.12] VGX-3100: Induction of cellular and humoral responses in Post-LEEP CIN 2/3 following immunotherapy with HPV16 & 18 SynCon™ DNA vaccines via electroporation N.Y. Sardesai* ¹ , J. Yan ² , X. Shen ¹ , M. Giffear ¹ , J. Lee ¹ , A.S. Khan ¹ , ¹ <i>Inovio Pharmaceuticals, USA</i> , ² <i>University of Pennsylvania, USA</i>		
19:00	Congress Dinner		
Tuesday 5 October 2010			
08:30 – 10:30	Plenary Session 6 <i>Park Congress</i> Antibody mediated protection by prophylactic and therapeutic vaccines Session chair: Clarisa Palatnik de Sousa		
08:30 – 08:55	[O6.1] Antibody mediated protection with DNA vaccines to highly lethal viruses Connie Schmaljohn, <i>US Military Medical Research, USA</i>		
08:55 – 09:20	[O6.2] Preclinical evaluation of influenza vaccines based on replication-deficient poxvirus vector MVA Guus F Rimmelzwaan, <i>Erasmus Medical Center, the Netherlands</i>		
09:20 – 09:30	[O6.3] Generation and characterisation of a humanized monoclonal antibody for prophylaxis and therapy of herpes simplex virus infections A. Krawczyk* ¹ , J. Krauss ³ , M. Arndt ³ , A-M Eis-Huebinger ² , K.E Schneeweis ² , M. Roggendorf ¹ , ¹ <i>Universitätsklinikum Essen, Germany</i> , ² <i>Universitätsklinikum Bonn, Germany</i> , ³ <i>Nationales Centrum für Tumorerkrankungen Heidelberg, Germany</i> , ⁴ <i>University College London, UK</i>		
09:30 – 09:40	[O6.4] Long-term vaccination with an HIV-1 immunogen in patients with HIV-1 chronic infection: impact on the induction of long-lasting HIV-1-specific T-cell responses and on virologic outcome E. Fernandez-Cruz*, L. Valor, C. Rodríguez-Sainz, J. Gil, J. Carbone, J. Navarro, et al, <i>Hospital General Universitario "Gregorio Marañón", Spain</i>		
09:40 – 09:50	[O6.5] Prevention of GBS disease by monoclonal antibodies directed against antigens identified by antigenome technology Z. Visram*, B.M. Senn, A.L. Meinke, M. Hanner, A. von Gabain, E. Nagy, <i>Intercell AG, Austria</i>		

09:50 – 10:00	[O6.6] Development of a VLP-peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies B.R. Champion* ¹ , A. Kjerrstrom ¹ , D. Hammond ¹ , J. Merson ¹ , G. Chikh ² , P. Saudan ³ , ¹ Pfizer Ltd, UK, ² Pfizer, Canada, ³ Cytos Biotechnology AG, Switzerland	
10:00 – 10:10	[O6.7] Development of a novel adjuvant platform for single-shot vaccines in neonates V. Gerdts* ¹ , M.-N. Kweon ² , S. Halperin ⁴ , R.E. Hancock ³ , A.A. Potter ¹ , L.A. Babiuk ⁵ , S. van den Hurk ¹ , ¹ Vaccine & Infectious Disease Organization, Canada, ² International Vaccine Institute, Korea, Republic of, ³ University of British Columbia, Canada, ⁴ Dalhousie University, Canada, ⁵ University of Alberta, Canada	
10:10 – 10:20	[O6.8] Bacterial ghost platform technology for vaccine development W. Lubitz*, <i>University of Vienna, Austria</i>	
10:20 – 10:30	[O6.9] A novel dual subunit vaccine against rotavirus and norovirus X. Jiang* ^{1,2} , M. Tan ^{1,2} , ¹ Cincinnati Children's Hospital Medical Center, USA, ² University of Cincinnati, USA	
10:30 – 11:00	Refreshment Break Level M1	
11:00 – 12:35	Breakout Session 3 Park Congress 1&2 Cancer Vaccines and other Novel Vaccines Session Chair: Alan Barrett	Breakout Session 4 Park Congress 3 Veterinary Vaccines and Animal Models Session Chair: John Oxford
11:00 – 11:25	[B3.1] Cancer vaccines: a tractable solution for an intractable problem Olivera Finn, <i>University of Pittsburgh School of Medicine, USA</i>	[B4.1] Development of parasite vaccines: an update Theo Schetters, <i>Intervet, The Netherlands</i>
11:25 – 11:35	[B3.2] Antitumoral efficacy of xenogenic dna coding for melanoma differentiation antigens in equine melanoma K. Mählmann* ¹ , K. Feige ¹ , C. Juhls ^{1,2} , A. Endmann ² , J.M.V. Müller ¹ , ¹ University of Veterinary Medicine Hannover, Germany, ² Mologen AG, Germany	[B4.2] New insight for Human Rhinovirus from viral evolutionary studies in tissue culture and humans Peter Nara, <i>Iowa State University, USA</i>
11:35 – 11:45	[B3.3] Novel vaccine strategies for cancer and infectious diseases by stimulating antigen-specific CD4+ T helper cells M. Xu*, X. Lu, D. Powell, N. Kallinteris, E. von Hofe, <i>Antigen Express, Inc, USA</i>	
11:45 – 11:55	[B3.4] Low dose cyclophosphamide enhances antitumor effects of therapeutic HPV DNA vaccine S.I. Pai*, S. Peng, S. Lyford-Pike, C.F. Hung, T.C. Wu, <i>Johns Hopkins Medical Institutions, USA</i>	[B4.3] Immunogenicities and protective efficacies of <i>Streptococcus suis</i> capsule conjugate vaccines in piglets N. Büttner*, C. Kock, A. Beineke, K-H Waldmann, P. Valentin-Weigand, C.G. Baums, <i>Tierärztliche Hochschule Hannover, Germany</i>
11:55 – 12:05	[B3.5] Prophylactic RNA vaccination against allergy - a safe and efficacious approach for the prevention of atopic disease E. Roesler, S. Scheibelhofer, E. Weinberger, J. Thalhamer, R. Weiss*, <i>University of Salzburg, Austria</i>	[B4.4] A live vaccine is safe and efficient to protect poultry against histomonosis M. Hess*, D. Liebhart, A. Zahoor, <i>University of Veterinary Medicine Vienna, Austria</i>
12:05 – 12:15	[B3.6] Development of protein capsular matrix vaccine technology K.P. Killeen*, A. Thanawastien, T. Griffin, <i>Matrivax R&D Corp, USA</i>	[B4.5] Deconstructing respiratory syncytial virus vaccine-enhanced disease in cotton rats C.A. Shaw*, M.A. Sackal, J.E. Monroe, K. Friedrich, T.M. Scalzo, G. Palladino, <i>Novartis, USA</i>
12:15-12:25	[B3.7] Oral vaccines: a new formulation that protects live bacterial vaccines from intestinal bile using bile adsorbing resins A. D. Edwards* ² , N. K. H. Slater ¹ , ¹ University of Cambridge, UK, ² University of Reading, UK	[B4.6] Comparison of adjuvant potential of a QS21-containing saponin and the CA3 and CA4 saponins from <i>Chiococca alba</i> (L.) hitch in murine vaccination against visceral leishmaniasis with the FML antigen L.M. Brandão ¹ , R.M. Borges ^{1,2} , D. Nico ¹ , A.J.R. da Silva ^{1,2} , C.B. Palatnik de Sousa* ¹ , ¹ Instituto de Microbiologia, Brazil, ² Núcleo de Pesquisas de Produtos Naturais UFRJ, Brazil
12:25-12:35	[B3.8] Intranasal vaccination: a viable alternative to injections? D. Marx*, <i>Aptar Pharma, Germany</i>	[B4.7] A novel method detecting bacterial surface proteins to evaluate the efficiency of <i>Streptococcus suis</i> serotype 2 vaccine W. Zhang*, G.J. Liu, C. P. Lu, <i>Nanjing Agricultural University, China</i>
12:35 – 14:00	Lunch Klimt Ballroom on level M1	
12:45- 13:45	Poster and Exhibition Session 3 level M1	
	Satellite symposium (Author workshop) Park Congress 3	

14:00 – 16:00	Plenary Session 7 Park Congress Vaccines in the Future Session Chair: Adolfo Garcia-Sastre
14:00 – 14:25	[O7.1] Scientific communication in the 21st Century: The role and vision of VACCINE Greg Poland, <i>Mayo Clinic and Foundation, USA</i>
14:25 – 14:50	[O7.2] Vaccines for Global Health Saladin Osmanov, <i>WHO</i>
14:50 – 15:15	[O7.3] Development of Vero-cell derived pandemic and seasonal influenza vaccines Noel Barrett, <i>Baxter, Austria</i>
15:15 – 15:25	[O7.4] Percutaneous immunization using ImmuPatch: needle-free vaccination that results in stronger T cell and antibody responses compared to traditional immunization routes A.C. Moore*, J.B. Carey, A. Crean, A. Vrdoljak, M. McGrath, C. O'Mahony, <i>University College Cork, Ireland</i>
15:25 – 15:35	[O7.5] Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass C.S. Rollier* ¹ , R. Alcock ² , M.G. Cottingham ¹ , D. Wyllie ¹ , M. Bregu ¹ , A.V. Hill ¹ , ¹ <i>Oxford University, UK</i> , ² <i>Cambridge Biostability Ltd, UK</i>
15:35 – 15:45	[O7.6] Characterization of candidate viral vaccines by asymmetric flow field flow fractionation C. Dworak, L. Pérez-Burgos*, G. Fuhrmann, C. Tauer, <i>Baxter Innovations GmbH, Austria</i>
15:45 – 15:55	[O7.7] Advanced immunology and imaging for vaccine evaluation: pre-clinical and animal rule A. Williams, S.A. Sharpe, B. Dove, M. Carroll*, <i>CEPR, Health Protection Agency, UK</i>
16:00	Closing summary Ray Spier and Shan Lu